New compression device aims to prevent blood clots
NCT ID NCT07287007
First seen Dec 17, 2025 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This study tests a new device called VenAir that squeezes the legs to improve blood flow and prevent blood clots. Researchers will compare it to a standard device in 105 healthy adults aged 20 to 64. Participants lie down while ultrasound measures blood flow with and without the device.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NO CONDITION, HEALTHY INDIVIDUALS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wellell Inc.
RECRUITINGNew Taipei City, 236044, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VenAir intermittent pneumatic compression device
What this could lead to
If successful, this could show that VenAir is a safe and effective option for preventing dangerous blood clots in the legs and lungs.
What could go wrong
This is an early study in healthy people, not patients. It only measures blood flow changes, not actual clot prevention, so real-world benefits are uncertain.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.